Vaxcyte's experimental pneumococcal vaccine VAX-31 meets Phase 3 endpoints, shares jump 35%
read at Endpoints ↗Positive readoutPositive
Vaxcyte announced that its experimental pneumococcal vaccine VAX-31 achieved its primary objectives in a Phase 3 trial involving adult participants.
The trial results showed that the vaccine met the predefined key endpoints, indicating it could provide effective protection against pneumococcal disease.
Following the announcement, Vaxcyte's stock rose sharply, with shares gaining about 35% in early trading on Monday.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Vaxcyte's pneumococcal vaccine succeeds in Phase 3, stock surges”
read at Endpoints ↗81 words · retrieved 1h ago
comments(0)
5-min edit window · permanent after that